Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

AbbVie Sues Generics Makers for Alleged Infringement of Orilissa Patents

  • Post author:PacConAdmin
  • Post published:November 3, 2022
  • Post category:Drug Industry Daily

AbbVie has filed a complaint against several generics producers — including Teva Pharmaceuticals and Novartis’ Sandoz unit — alleging the companies infringed on patents for its endometriosis drug Orilissa (elagolix)…

Continue ReadingAbbVie Sues Generics Makers for Alleged Infringement of Orilissa Patents

FDA Finalizes Guidance on Cross Labeling of Combination Oncology Drugs

  • Post author:PacConAdmin
  • Post published:November 3, 2022
  • Post category:Drug Industry Daily

Sponsors should be prepared to discuss proposed labeling for combination oncology drug regimens with the FDA in pre-application meetings, the agency said in a final guidance released yesterday. Source: Drug…

Continue ReadingFDA Finalizes Guidance on Cross Labeling of Combination Oncology Drugs

FDA Warns Lupin for Lack of Plan to Correct Cleaning and Contamination Issues

  • Post author:PacConAdmin
  • Post published:November 2, 2022
  • Post category:Drug Industry Daily

The FDA handed Lupin Limited a warning letter citing the company’s failure to correct cross-contamination issues noted in an inspection of its manufacturing plant in Palghar, India, earlier this year.…

Continue ReadingFDA Warns Lupin for Lack of Plan to Correct Cleaning and Contamination Issues

Arcturus Inks Multimillion-Dollar Deal With CSL to Develop mRNA Vaccines

  • Post author:PacConAdmin
  • Post published:November 2, 2022
  • Post category:Drug Industry Daily

For $200 million up front and a possible $4.3 billion later, Arcturus Therapeutics has agreed to a vaccine collaboration with CSL Seqirus. Source: Drug Industry Daily

Continue ReadingArcturus Inks Multimillion-Dollar Deal With CSL to Develop mRNA Vaccines

Two Big-Ticket Hemophilia Gene Therapies Would Be Worth the Cost, ICER Says

  • Post author:PacConAdmin
  • Post published:November 2, 2022
  • Post category:Drug Industry Daily

Two gene replacement therapies to combat hemophilia are worth multimillion dollar price tags because they would eliminate the need for ongoing treatment with high-priced anticoagulant drugs, says the Institute for…

Continue ReadingTwo Big-Ticket Hemophilia Gene Therapies Would Be Worth the Cost, ICER Says

FDA Advisors Vote in Favor of CDER’s Quality Management Maturity Program

  • Post author:PacConAdmin
  • Post published:November 2, 2022
  • Post category:Drug Industry Daily

An FDA advisory committee voted 9-0 yesterday in favor of the agency’s proposal to create an as-yet undefined rating system to incentivize drug manufacturers to adopt more mature quality management…

Continue ReadingFDA Advisors Vote in Favor of CDER’s Quality Management Maturity Program

Novartis Sues Generic Companies to Protect Entresto Patent

  • Post author:PacConAdmin
  • Post published:November 1, 2022
  • Post category:Drug Industry Daily

Novartis has filed a complaint against several generic drugmakers for allegedly infringing on a patent for its blockbuster heart failure drug Entresto (sacubitril/valsartan). Source: Drug Industry Daily

Continue ReadingNovartis Sues Generic Companies to Protect Entresto Patent

Pfizer Data for RSV Vaccine Candidate in Pregnant Women Mostly Positive

  • Post author:PacConAdmin
  • Post published:November 1, 2022
  • Post category:Drug Industry Daily

Pfizer announced Tuesday that its bivalent respiratory syncytial virus (RSV) vaccine candidate met one of two primary endpoints when administered to pregnant participants to help protect their infants from RSV…

Continue ReadingPfizer Data for RSV Vaccine Candidate in Pregnant Women Mostly Positive

FDA Issues Draft Guidance on the OTC Monograph User Fee Program

  • Post author:PacConAdmin
  • Post published:November 1, 2022
  • Post category:Drug Industry Daily

A new FDA draft guidance the over-the-counter (OTC) monograph drug user fee program outlines the program’s features and procedures, including the types of fees, due dates, the process for submitting…

Continue ReadingFDA Issues Draft Guidance on the OTC Monograph User Fee Program

FDA Updates Expanded Access Guidance With Cures Act and FDARA Requirements

  • Post author:PacConAdmin
  • Post published:November 1, 2022
  • Post category:Drug Industry Daily

The FDA has revised its October 2017 draft guidance on the Expanded Access program, adding information on eligibility criteria, submission process and safeguards intended to protect patients and preserve the…

Continue ReadingFDA Updates Expanded Access Guidance With Cures Act and FDARA Requirements
  • Go to the previous page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.